Phathom Pharmaceuticals, Inc. (PHAT) · Oct 26, 2026 · Other events
FDA comment docket — Comments due November 23, 2026; exclusivity remains in effect
Phathom’s FDA docket adds another legal hurdle around VOQUEZNA’s 2032 exclusivity, but the protection remains in effect for now.
Phathom is a commercial-stage GI company building its business around the growing U.S. launch of VOQUEZNA while advancing additional vonoprazan uses, including non-erosive GERD and eosinophilic esophagitis. VOQUEZNA generated $74.3 million of second-quarter 2026 revenue, and the company had reported roughly 1.7 million prescriptions filled by July 2026. The filing does not remove current protection, but it turns a previously contained exclusivity dispute into a broader administrative and litigation process. The FDA has opened a public docket on the legal and regulatory questions raised by BDR, with comments due November 23, 2026. 〔0〕 A second purported ANDA filer, Saba Ilac, also says it intends to seek consolidation with BDR’s case. 〔1〕 The near-term business position is unchanged, but the downside scenario is more credible than it was before this notice. Phathom still says VOQUEZNA’s 10-year NCE exclusivity runs through May 3, 2032, and the filing states that the exclusivity “remains in effect.” 〔2〕 However, an adverse FDA or court outcome could allow generic applications to be received or approved earlier, putting the company’s core commercial franchise at risk. This is not a loss of exclusivity today; it is an expansion of the process that could determine how long the protection lasts. Bottom line: The filing is mixed rather than an immediate setback: VOQUEZNA keeps its claimed protection for now, but the exclusivity challenge now involves both a formal FDA comment process and a second potential challenger.
FDA docket comments due November 23, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!